CADL News and Press, Candel Therapeutics Inc. From 05/22/24

NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FM...

NEEDHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will be hosting a webcasted R...

2024-05-16 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-14 14:35:37 ET More on Candel Therapeutics Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer Candel Therapeutics receives FDA orphan drug designation for its pancreatic cancer treatment Candel stock soars on positive data from m...

Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer Phase 2 topline overall survival data for CAN-2409 in non-small cell lung cancer (NSCLC), to be presented at ASCO on June 3, 2024 On track for top...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-04-27 14:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accept...

2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac  ( CVAC ) +5% . CorMedix  ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...

2024-04-15 16:35:18 ET Summary Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designati...